59th Medical Wing, Office of Science & Technology, Joint Base San Antonio-Lackland, TX 78236, USA.
Nanomedicine (Lond). 2019 Oct;14(20):2749-2762. doi: 10.2217/nnm-2019-0192. Epub 2019 Oct 23.
Nanomedicine has matured significantly in the past 20 years and a number of nanoformulated therapies are cleared by regulatory agencies for use across the globe. Transplant medicine is one area that has significantly benefited from the advancement of nanomedicine in recent times. However, while nanoparticle-based therapies have improved toxicological profiles of some drugs, there are still a number of aspects regarding the biocompatibility and toxicity of nanotherapies that require further research. The goal of this article is to review toxicological profiles of immunosuppressant therapies and their conversion into nanomedicine formulations as well as introduce future challenges associated with current and toxicological models.
在过去的 20 年中，纳米医学有了显著的发展，许多纳米制剂疗法已经通过监管机构的批准，在全球范围内使用。移植医学是近年来受益于纳米医学发展的一个领域。然而，尽管基于纳米颗粒的疗法改善了一些药物的毒理学特性，但纳米疗法的生物相容性和毒性仍有许多方面需要进一步研究。本文的目的是综述免疫抑制剂治疗的毒理学特性及其转化为纳米医学制剂，并介绍当前和未来毒理学模型所面临的挑战。
